Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Esophageal Cancer: early-phase trial registry
63 of 132 indexed Esophageal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #88 of 28,707 conditions by registered trial count.
132 US clinical trials · 63 currently recruiting · #88 of 28,707 conditions by registered trial count
Esophageal Cancer: 132 US clinical trials tracked, 63 recruiting.
Esophageal Cancer is the subject of 132 registered US clinical trials on ClinicalTrials.gov, 63 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 10 of these trials.
Enrollment posture brief
Registry condition esophageal-cancer
OPEN 63 | RECR 48% | LATE 8 | EARLY 84 | RANK #88 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Alcohol Drinking (48% recruiting · 86 trials)
Esophageal Cancer lists 63 open slots (48% of 132 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Esophageal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Esophageal Cancer is recruiting above its size-band peers.
63 of 132 indexed trials (47.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Esophageal Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 10 of 132 trials (7.6%). 89 distinct sponsors appear on at least one study for this condition label.
-
Typical Esophageal Cancer enrolment sits around 80 participants.
Median target enrolment is 80 among the 124 trials that report a genuine target (sentinel values excluded). 69 of those (55.6%) plan for fewer than 100 participants.
-
Esophageal Cancer research is mostly interventional.
106 interventional and 26 observational studies make up this index (80.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
132 total, page 3 of 3
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
Jonsson Comprehensive Cancer Center
NCT00020761
Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
Alliance for Clinical Trials in Oncology
NCT00040859
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
NCT00054457
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
Northwestern University
NCT00711412
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Cancer Institute (NCI)
NCT00924027
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
NCT00130689
Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
Nasser Hanna, M.D.
NCT00319735
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Jonsson Comprehensive Cancer Center
NCT00003748
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03652077
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT01913639
A Study of Durvalumab (MEDI4736) in Esophageal Cancer
Shadia Jalal, MD
NCT02639065
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co.
NCT03518554
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
NCT00917462
FDG-PET-CT and Biomarkers in Esophageal Cancer
M.D. Anderson Cancer Center
NCT00833625
Photodynamic Therapy in Treating Patients With Early Esophageal Cancer
Roswell Park Cancer Institute
NCT00002935
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
Georgetown University
NCT00003125
Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
Memorial Sloan Kettering Cancer Center
NCT00002711
Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy
Vanderbilt-Ingram Cancer Center
NCT02324881
M1231 in Participants With Solid Tumors
EMD Serono Research & Development Institute
NCT04695847
Is Screening for Esophageal Pathology in Asymptomatic Patients Post-Treatment for Head and Neck Cancer Beneficial?
University of California, Davis
NCT00583934
Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
Emory University
NCT01490749
Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Duke University
NCT00281788
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
Weill Medical College of Cornell University
NCT01386346
NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer
Dana-Farber Cancer Institute
NCT01808417
Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium
Pentax Medical
NCT02729753
Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.
CSA Medical
NCT00754468
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
SWOG Cancer Research Network
NCT00032123
BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy
Bristol-Myers Squibb
NCT00017043
Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer
Albany Medical College
NCT00004257
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
Memorial Sloan Kettering Cancer Center
NCT00006245
DX-8951f in Treating Patients With Metastatic Stomach Cancer
Daiichi Sankyo
NCT00017212
Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach
Radiation Therapy Oncology Group
NCT00009880
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 49 |
| Phase 2 | 35 |
| Phase 3 | 5 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Esophageal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Esophageal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Esophageal Cancer page
132 registered trials, 63 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 63 Esophageal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Esophageal Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Esophageal Cancer condition card totals 132 registered trials; most-linked intervention radiation therapy; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.